In vivo KPT-350 treatment decreases cortical hyperexcitability following traumatic brain injury

ABSTRACT

Primary Objective

We tested whether KPT-350, a novel selective inhibitor of nuclear export, could attenuate cortical network hyperexcitability, a major risk factor for developing post-traumatic epilepsy (PTE) following traumatic brain injury (TBI).

Research Design

All mice in this study underwent TBI and were subsequently treated with either KPT-350 or vehicle during the post-injury latent period. Half of the animal cohort was used for electrophysiology while the other half was used for immunohistochemical analysis.

Methods and Procedures

TBI was induced using the controlled cortical impact (CCI) model. Cortical network activity was recorded by evoking field potentials from deep layers of the cortex and analyzed using Matlab software. Immunohistochemistry coupled with fluorescence microscopy and Image J analysis detected changes in neuronal and glial markers.

Main Outcomes and Results

KPT-350 attenuated TBI-associated epileptiform activity and restored disrupted input-output responses in cortical brain slices. In vivo KPT-350 treatment reduced the loss of parvalbumin-(+) GABAergic interneurons after CCI but did not significantly change CCI-induced loss of somatostatin-(+) GABAergic interneurons, nor did it reduce reactivity of GFAP and Iba1 glial markers.

Conclusion

KPT-350 can prevent cortical hyperexcitability and reduce the loss of parvalbumin-(+) GABAergic inhibitory neurons, making it a potential therapeutic option for preventing PTE.

KEYWORDS:

• Traumatic brain injury
• epilepsy
• neuronal hyperexcitability
• XPO1 inhibitors
• selective inhibitors of nuclear export

Acknowledgments

The authors would like to thank Dr. Ramon Diaz-Arrastia and Dr. Alon Friedman for their helpful discussion of this work.

Declaration of interest

This work was funded by Karyopharm Therapeutics, Inc as part of a sponsored research agreement with Tufts University. Sharon Shacham and Sharon Tamir are employees of Karyopharm Therapeutics, Inc.

Additional information

Funding

This work was supported by Karyopharm Therapeutics.